Skip to main content
    P

    Puma Biotechnology Inc (PBYI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.34
    -0.43 (-5.53%)

    Market Cap: $401.70M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Puma Biotechnology Inc (PBYI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Puma Biotechnology reported revenue of $228.37M for the fiscal year ended Dec 31, 2025, down 0.9% from the year before. That year, net income was $31.11M with a net margin of 13.6%, operating cash flow was $41.80M and free cash flow was $41.73M. The quarter ended Sep 30, 2026 had revenue of $55.06M and net income of $5.96M.

    Revenue and Margins

    The operating margin was 16.3% in the fiscal year ended Dec 2025, the highest of the 8 years shown with an operating margin. Over the 8 years to Dec 2025, revenue grew from $27.68M, a compound annual rate of 30.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$228.37M-0.9%74.5%16.3%13.6%
    Dec 2024$230.47M-2.2%72.1%13.4%13.1%
    Dec 2023$235.64M+3.3%73.4%13.9%9.2%
    Dec 2022$228.03M-9.9%75.8%10.4%0.0%
    Dec 2021$253.16M+12.5%74.8%0.5%-11.5%
    Dec 2020$225.11M-17.3%82.5%-13.5%-26.7%
    Dec 2019$272.26M+8.5%86.5%-14.3%-27.8%
    Dec 2018$250.99M+806.6%86.2%-37.7%-45.3%
    Dec 2017$27.68MN/A79.9%-1056.1%-1054.6%
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 2.7% from the year before. In the quarter ended Sep 2026, net income fell 32.6% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$228.37M$230.47M$235.64M$228.03M$253.16M$225.11M$272.26M$250.99M$27.68M$0
    Cost of revenue$58.16M$64.40M$62.68M$55.09M$63.70M$39.37M$36.81M$34.62M$5.57M$0
    Gross profit$170.21M$166.06M$172.96M$172.94M$189.45M$185.74M$235.44M$216.37M$22.11M$0
    Research and development$62.07M$54.94M$50.38M$59.24M$71.87M$97.65M$132.85M$164.85M$207.81M$222.80M
    Operating income$37.30M$30.97M$32.64M$23.72M$1.29M-$30.40M-$39.05M-$94.66M-$292.39M-$276.60M
    Net income$31.11M$30.28M$21.59M$2.00K-$29.13M-$59.99M-$75.59M-$113.58M-$291.95M-$276.01M
    EBITDA$49.26M$43.35M$44.92MN/A$3.30MN/AN/AN/A-$289.68M-$272.82M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$55.06M$56.50M$44.81M$75.45M$54.48M$52.44M$46.01M$59.08M$80.54M$47.08M$43.77M$72.18M
    Gross profit$39.86M$44.03M$34.39M$52.33M$42.30M$40.13M$35.45M$45.16M$51.45M$36.42M$33.04M$47.85M
    Operating income$5.27M$7.58M-$3.83M$17.11M$9.57M$6.64M$3.98M$13.37M$22.08M-$2.18M-$2.30M$14.80M
    Net income$5.96M$8.19M-$3.75M$13.44M$8.84M$5.86M$2.97M$19.30M$20.32M-$4.53M-$4.82M$12.27M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $22.52M by $7.11M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$216.30M$213.33M$230.53M$222.06M$226.59M$244.22M$234.91M$259.12M$165.53M$252.79M
    Current assets$162.69M$147.66M$156.19M$134.28M$140.02M$146.14M$166.30M$203.00M$106.39M$236.47M
    Cash and equivalents$29.64M$69.22M$84.58M$76.20M$63.13M$85.29M$60.04M$108.42M$81.70M$194.49M
    Total liabilities$85.96M$121.21M$177.09M$200.45M$229.03M$250.17M$217.44M$224.82M$112.22M$42.97M
    Short-term debt$22.52M$45.33M$34.00M$0$3.57M$14.29M$0N/A$48.48MN/A
    Long-term debtN/A$21.72M$65.66M$98.31M$97.09M$84.03M$94.96M$151.89M$48.48M$0
    Shareholder equity$130.34M$92.13M$53.44M$21.61M-$2.45M-$5.95M$17.46M$34.31M$53.30M$209.82M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$202.77M$192.74M$192.70M$216.30M$202.86M$194.92M$196.18M$213.33M$220.72M$205.00M$214.15M$230.53M
    Total liabilities$56.15M$54.19M$64.28M$85.96M$87.59M$90.20M$99.07M$121.21M$149.63M$156.49M$163.17M$177.09M
    Cash and equivalents$41.55M$36.54M$36.19M$29.64M$53.52M$54.66M$63.03M$69.22M$67.26M$67.15M$76.75M$84.58M
    Shareholder equity$146.61M$138.54M$128.42M$130.34M$115.27M$104.72M$97.11M$92.13M$71.09M$48.51M$50.98M$53.44M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 99.8% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$41.80M$38.92M$27.01M-$15.83M$20.65M$773.00K$22.38M-$24.11M-$172.47M-$141.69M
    Capital expenditures$71.00K$56.00K$140.00K$0$0$46.00K$306.00K$609.00K$431.00K$7.28M
    Free cash flow$41.73M$38.86M$26.87M-$15.83M$20.65M$727.00K$22.07M-$24.71M-$172.90M-$148.97M
    Share repurchasesN/AN/AN/A$277.00K$0$0N/AN/AN/AN/A
    Investing cash flow-$36.19M-$20.44M-$19.13M$7.10M-$10.88M$33.40M$5.16M-$57.62M-$15.44M$142.19M
    Financing cash flow-$45.20M-$33.85M$0$12.22M-$31.93M-$9.93M-$67.07M$108.45M$75.11M$162.43M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$14.58M$1.62M$15.42M$14.42M$9.69M$14.08M$3.61M$15.61M$11.04M$1.03M$11.25M$10.46M
    Capital expendituresN/AN/A$0$36.00K$26.00K$20.00K$61.00K$16.00K$20.00K$20.00K$0$45.00K
    Free cash flowN/AN/A$15.42M$14.38M$9.66M$14.06M$3.55M$15.59M$11.02M$1.01M$11.25M$10.41M
    Last 12 quarters

    Frequently Asked Questions About PBYI

    What is Puma Biotechnology's annual revenue?

    Puma Biotechnology reported revenue of $228.37M for the fiscal year ended Dec 31, 2025.

    How fast is Puma Biotechnology's revenue growing?

    Revenue was down 0.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.0%.

    Is Puma Biotechnology profitable?

    Yes. Puma Biotechnology reported net income of $31.11M for the fiscal year ended Dec 31, 2025, with a net margin of 13.6%.

    How much free cash flow does PBYI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $41.80M minus capital expenditures of $71.00K produced free cash flow of $41.73M.

    How much debt does Puma Biotechnology have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $22.52M and cash and equivalents of $29.64M.